As an attending hematopathologist I am involved in diagnostic work up and follow up after therapy of patients diagnosed with hematologic malignancies including AML, ALL, MDS and MDS/MPN. I am interested in understanding the pathogenesis of hematopoietic tumors and how specific events required for leukemic transformation can be targeted for therapy. In addition, as part of collaborative research projects I have been involved in the analyses of mice in models of normal and malignant hematopoiesis.
Department of Pathology, Univeristy of Chicago
Chicago
Fellowship - Hematopathology
2008Department of Pathology, Univeristy of Chicago
Chicago
Residency - Clinical Pathology
2007Ben May Department of Cancer Research, University of Chicago
Chicago
Post Doctoral Fellowship - Cancer Biology, Normal and Malignant Hematopoiesis
2004INSERM U517, University of Burgundy
Dijon, France
Post Doctoral Fellowship - Cancer Biology, Apoptosis
2002All India Institute of Medical Sciences
New Delhi, India
PhD - Hematology
2000Motilal Nehru Medical College
Allahabad, India
MBBS - Medicine
1992PHF6 suppresses self-renewal of leukemic stem cells in AML.
PHF6 suppresses self-renewal of leukemic stem cells in AML. Leukemia. 2024 Sep; 38(9):1938-1948.
PMID: 39004675Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms.
Real world predictors of response and 24-month survival in high-grade TP53-mutated myeloid neoplasms. Blood Cancer J. 2024 06 18; 14(1):99.
PMID: 38890297Malignant progression of preleukemic disorders.
Malignant progression of preleukemic disorders. Blood. 2024 05 30; 143(22):2245-2255.
PMID: 38498034Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis. Blood Cancer Discov. 2024 May 01; 5(3):164-179.
PMID: 38150184SETBP1 sets the stage.
SETBP1 sets the stage. Blood. 2024 04 04; 143(14):1323-1324.
PMID: 38573606PHF6 suppresses self-renewal of leukemic stem cells in AML.
PHF6 suppresses self-renewal of leukemic stem cells in AML. bioRxiv. 2024 Jan 18.
PMID: 38260439Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2024 01 09; 8(1):164-171.
PMID: 38039510Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis.
Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis. Blood Cancer Discov. 2023 Dec 27.
PMID: 38150184Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors.
Durable responses in acute lymphoblastic leukaemia with the use of FLT3 and IDH inhibitors. Br J Haematol. 2024 Apr; 204(4):1238-1242.
PMID: 38073116Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults.
View All Publications
Socioeconomic determinants of the biology and outcomes of acute lymphoblastic leukemia in adults. Blood Adv. 2023 Dec 01.
PMID: 38039510